NEW YORK, March 10, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Moments ago, Analysts Review released new research updates concerning several important developing situations including OncoGenex (NASDAQ: OGXI), Oxford Immunotec (NASDAQ: OXFD), Quidel (NASDAQ: QDEL), Response Genetics (NASDAQ: RGDX), and Trinity Biotech (NASDAQ: TRIB). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA(R) research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

OGXI Research Report: ( http://get.analystsreview.com/pdf/?c=OncoGenex&d=10-Mar-2015&s=OGXI ),

OXFD Research Report: ( http://get.analystsreview.com/pdf/?c=Oxford%20Immunotec&d=10-Mar-2015&s=OXFD ),

QDEL Research Report: ( http://get.analystsreview.com/pdf/?c=Quidel&d=10-Mar-2015&s=QDEL ),

RGDX Research Report: ( http://get.analystsreview.com/pdf/?c=Response%20Genetics&d=10-Mar-2015&s=RGDX ),

TRIB Research Report: ( http://get.analystsreview.com/pdf/?c=Trinity%20Biotech&d=10-Mar-2015&s=TRIB ).

============

--

Analyst Update: Clinical Trials, Participation in Upcoming Events, and Approvals

Reviewed by: Rohit Tuli, CFA(R)

The US equity indices closed higher on Monday as investors hunted for buying opportunities after a sharp selloff on Friday. Strong jobs report also raised expectations among Wall Street traders that the Federal Reserve may increase interest rates soon. The S&P 500 inched up 8.17 points, or 0.39%, to end at 2,079.43, and the Dow Jones Industrial Average gained 138.94 points or 0.78% to 17,995.72. The tech-heavy NASDAQ was up 15.07 points or 0.31% to close at 4,942.44. Reports from Labor Department also highlighted that U.S. payrolls grew by a seasonally adjusted 295,000 in February, while the unemployment rate fell to 5.5%, which is within the Fed's target zone for rate increases. European benchmark indices mostly ended lower on Monday, on concerns over Greece as the head of Euro Zone finance ministers urged Greece to buckle down to serious talks on implementing a reform programme to urgently secure required funds from its international creditors. Germany's DAX 30 gained 31.14 points or 0.27% to 11,582.11, and Eurostoxx 50 was lower 7.34 points or 0.20% to 3,610.28. France's CAC 40 declined 27.15 points or 0.55% to 4,937.20.

OncoGenex Pharmaceuticals Inc. (OncoGenex) and Sarah Cannon, Hospital Corporation of America's global cancer enterprise, announced that patient enrollment has been completed in the Spruce(TM) clinical trial.

Oxford Immunotec Global PLC (Oxford Immunotec), a commercial-stage diagnostics company, announced the enrollment of first patients in the PROTECT Study. The PROTECT study is a pivotal clinical trial designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT(R).CMV and T-SPOT.PRT products.

Quidel Corporation (Quidel), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, will present at Barclays Global Healthcare Conference, to be held at the Loews Miami Beach hotel in Miami, Florida, on March 12, 2015.

Response Genetics, Inc. (Response Genetics), a company focused on the development and sale of molecular diagnostic tests related to cancer therapy, has received approval from the New York State Department of Health to offer, market and report results of the Company's ResponseDX(R) tests to healthcare providers in the State of New York.

Trinity Biotech plc (Trinity Biotech), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that it has shipped Meritas Troponin I product to the USA for the immediate recommencement of US clinical trials on its Troponin I point-of-care product.

--

About Analysts Review

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA(R). An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review